NASDAQ:CALC CalciMedica (CALC) Stock Price, News & Analysis $0.68 -0.01 (-0.86%) As of 01:09 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CalciMedica Stock (NASDAQ:CALC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CalciMedica alerts:Sign Up Key Stats Today's Range$0.65▼$0.6950-Day Range$0.52▼$0.9052-Week Range$0.46▼$7.20Volume38,755 shsAverage Volume888,177 shsMarket Capitalization$10.77 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingHold Company Overview CalciMedica, Inc. (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses. The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia. Early-phase data suggest that CRAC channel inhibition can reduce inflammatory cytokine release and support organ function in critically ill patients. CalciMedica pursues a development strategy that combines rigorous clinical evaluation with strategic collaborations to expedite potential regulatory approvals and commercialization. Operating primarily in the United States, the company works closely with academic centers and healthcare organizations to advance its pipeline. By targeting calcium signaling in innate immune cells, CalciMedica aims to fill unmet medical needs in acute inflammatory diseases and improve outcomes for high-risk patient populations.AI Generated. May Contain Errors. Read More CalciMedica Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreCALC MarketRank™: CalciMedica scored higher than 57% of companies evaluated by MarketBeat, and ranked 435th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingCalciMedica has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialCalciMedica has a consensus price target of $13.00, representing about 1,820.2% upside from its current price of $0.68.Amount of Analyst CoverageCalciMedica has only been the subject of 1 research reports in the past 90 days.Read more about CalciMedica's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CalciMedica are expected to decrease in the coming year, from ($1.21) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CalciMedica is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CalciMedica is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.83% of the float of CalciMedica has been sold short.Short Interest Ratio / Days to CoverCalciMedica has a short interest ratio ("days to cover") of 1.11, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CalciMedica has recently decreased by 54.87%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCalciMedica does not currently pay a dividend.Dividend GrowthCalciMedica does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.98 News SentimentCalciMedica has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for CalciMedica this week, compared to 2 articles on an average week.Search Interest3 people have searched for CALC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CalciMedica insiders have not sold or bought any company stock.Percentage Held by Insiders41.55% of the stock of CalciMedica is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsCalciMedica has minimal institutional ownership at this time.Read more about CalciMedica's insider trading history. Receive CALC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CalciMedica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CALC Stock News HeadlinesCalciMedica, Inc.: CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesMay 12 at 5:15 PM | finanznachrichten.deCalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesMay 12 at 7:00 AM | prnewswire.comThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on day one often end up holding the bag when early insiders cash out. Analyst Michael Robinson believes the smarter move is a little-known partner company supplying critical technology to Elon's so-called 'Project Unlimited' - an undertaking he says could unlock $100 trillion in potential growth. You need to be positioned before the June 2026 listing date.May 14 at 1:00 AM | Weiss Ratings (Ad)CalciMedica (CALC) to Release Quarterly Earnings on WednesdayMay 11 at 3:51 AM | americanbankingnews.comCalciMedica, Inc. Common Stock (CALC)May 1, 2026 | nasdaq.comCalciMedica (CALC) price target decreased by 24.39% to 10.54March 27, 2026 | msn.comCalciMedica Receives Nasdaq Deficiency Notices on Listing StandardsMarch 20, 2026 | theglobeandmail.comCalciMedica, Inc.: CalciMedica Reports 2025 Financial Results and Provides Clinical UpdatesMarch 3, 2026 | finanznachrichten.deSee More Headlines CALC Stock Analysis - Frequently Asked Questions How have CALC shares performed this year? CalciMedica's stock was trading at $6.59 on January 1st, 2026. Since then, CALC stock has decreased by 89.7% and is now trading at $0.6770. How were CalciMedica's earnings last quarter? CalciMedica Inc. (NASDAQ:CALC) released its quarterly earnings results on Tuesday, March, 3rd. The company reported ($0.69) earnings per share for the quarter. When did CalciMedica IPO? CalciMedica (CALC) raised $90 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 5,625,000 shares at a price of $15.00-$17.00 per share. Who are CalciMedica's major shareholders? CalciMedica's top institutional shareholders include 180 Wealth Advisors LLC (0.80%). Insiders that own company stock include Sanderling Venture Partners Vi, Robert N Wilson, Eric W Roberts, Sudarshan Hebbar, Kenneth A Stauderman, A Rachel Leheny and Stephen Bardin. View institutional ownership trends. How do I buy shares of CalciMedica? Shares of CALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CalciMedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that CalciMedica investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Castor Maritime (CTRM). Company Calendar Last Earnings3/03/2026Today5/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CALC's financial health is in the Red zone, according to TradeSmith. CALC has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CALC CIK1534133 Webwww.graybug.vision Phone858-952-5500FaxN/AEmployees30Year Founded2007Price Target and Rating Average Price Target for CalciMedica$13.00 High Price Target$16.00 Low Price Target$10.00 Potential Upside/Downside+1,820.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.56 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,093.51% Return on Assets-127.83% Debt Debt-to-Equity RatioN/A Current Ratio3.58 Quick Ratio3.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.46) per share Price / Book-1.47Miscellaneous Outstanding Shares15,744,000Free Float9,202,000Market Cap$10.66 million OptionableNo Data Beta0.85 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CALC) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersMicroscopic Footage Shows Immune Cells Attacking CancerEarly human trial data from one NASDAQ-listed biotech showed up to a 63.7% reduction in cancer burden using it...Market Tactic | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredThe Rare Earth Shift Few Saw ComingRare earth elements are the hidden backbone of electric vehicles, modern defense technology, and advanced elec...i2i Marketing Group, LLC | SponsoredYou'll buy SpaceX at $1.75 trillion. Insiders bought at $20 billion.Insiders bought SpaceX at $20 billion. Banks got in at $100 billion. By the time it hits your brokerage accoun...Behind the Markets | SponsoredPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...The Tomorrow Investor | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredThe system holding the dollar together is gone…Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
